Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute.

Authors

Dana Shelton Thompson

Tennessee Oncology, PLLC/SCRI, Nashville, TN

Dana Shelton Thompson , B. Stephens Dudley , John A. Bismayer , Victor G. Gian , William McIver Merritt , Robert C. Whorf , Howard A. Burris III, John D. Hainsworth

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus either Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.

First Author: Thomas J. Herzog

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).

First Author: Emmanuelle Samalin

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.

First Author: Frederik Marme

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.

First Author: Jianqing Zhu